Tirzepatide for Weight Loss: Complete Guide

Quick Answer

Tirzepatide (Zepbound for obesity, Mounjaro for diabetes) produces an average 20.9% body weight loss at 72 weeks — the highest ever recorded for an approved weight loss medication. It's a dual GLP-1/GIP receptor agonist taken as a once-weekly injection. For a 250 lb person, average results are about 52 lbs lost.

What Is Tirzepatide?

Tirzepatide is a novel dual incretin receptor agonist developed by Eli Lilly. It's the first medication approved for obesity that activates two receptors simultaneously:

GLP-1 receptor (glucagon-like peptide-1) — the same receptor targeted by semaglutide
GIP receptor (glucose-dependent insulinotropic polypeptide) — an additional incretin receptor that appears to amplify weight loss through complementary pathways

Brand names:

Mounjaro — 5, 10, or 15 mg weekly injection; FDA-approved for type 2 diabetes (2022)
Zepbound — Same doses; FDA-approved for obesity and overweight with comorbidities (2023)

Why Tirzepatide Outperforms Semaglutide

The GIP receptor co-activation is the likely explanation for tirzepatide's superior weight loss. The exact mechanism is still being elucidated, but research suggests:

GIP receptor activation in the brain's reward circuit may have additive appetite-suppressing effects
GIP and GLP-1 receptor activation together reduce energy intake through partially independent pathways
GIP receptor activation may directly reduce fat cell size and lipid accumulation

The result is approximately 5–6 percentage points more average weight loss compared to semaglutide, across all patient subgroups.

Clinical Trial Results: SURMOUNT Program

The landmark SURMOUNT-1 trial enrolled 2,539 adults with obesity (no diabetes), randomized to tirzepatide or placebo for 72 weeks:

Dose	Average Weight Loss	Lost ≥20%
5 mg	-15.0%	32%
10 mg	-19.5%	51%
15 mg	-20.9%	57%
Placebo	-3.1%	1%

Notably, 36% of patients on the 15 mg dose lost more than 25% of their body weight — a result previously only seen with bariatric surgery.

SURMOUNT-2 (type 2 diabetes): 15 mg tirzepatide produced -14.7% weight loss — significant improvement even in a harder-to-treat population.

SURMOUNT-MMO (cardiovascular outcomes): A major cardiovascular outcomes trial completed in 2025, results in press.

SURMOUNT-OSA: Tirzepatide reduced sleep apnea severity (AHI) by 24–25% in adults with moderate-to-severe sleep apnea — some patients were able to discontinue CPAP.

Dosing Schedule

Weeks	Zepbound Dose
1–4	2.5 mg
5–8	5 mg
9–12	7.5 mg
13–16	10 mg
17–20	12.5 mg
21+	15 mg (target)

The titration to maximum dose takes 20 weeks. Some patients remain at 10 mg or 12.5 mg if 15 mg produces intolerable side effects.

Side Effects

Similar to semaglutide — primarily gastrointestinal:

Common: Nausea (44%), diarrhea (23%), vomiting (21%), constipation (19%). These typically peak at weeks 2–8 with each dose increase and diminish thereafter.

Serious (rare): Pancreatitis, gallbladder disease, hypoglycemia (when combined with insulin or sulfonylureas).

Contraindicated in: Personal or family history of medullary thyroid carcinoma; MEN2; prior hypersensitivity to tirzepatide.

Nausea rates with tirzepatide are broadly similar to semaglutide at equivalent dose-response levels, though some providers note tirzepatide's side effect profile may be slightly more favorable.

Cost and Access

List price: Approximately $1,060/month for Zepbound (US, 2025) — somewhat lower than Wegovy

Eli Lilly savings program: Significant discounts for commercially insured patients; as low as $25/month for eligible patients

Self-pay vials: Eli Lilly introduced lower-cost self-pay vials in 2024 at approximately $399–$549/month

Telehealth: Widely available through online platforms; typically a faster prescription pathway than in-person visits

Get a Tirzepatide Prescription Online

Bottom Line

Tirzepatide is currently the most effective approved weight loss medication available. At 15 mg weekly, it produces average weight loss of 20.9% — approaching what was previously only achievable with bariatric surgery. For most patients, it's the first-choice option if cost and access allow.